Patents by Inventor Collin Regan

Collin Regan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230234925
    Abstract: The present disclosure relates to compounds of Formula (I) that modulate the activity of G-protein coupled receptor 52 (GPR52), pharmaceutically acceptable salts of compounds of Formula (I), and pharmaceutical compositions thereof. Compounds, pharmaceutical salts of compounds, and pharmaceutical compositions of the present disclosure are directed to methods useful in the treatment or prophylaxis of a neurological disease or disorder and conditions related thereto.
    Type: Application
    Filed: April 21, 2021
    Publication date: July 27, 2023
    Inventors: Juan Pablo Cueva-Garcia, Neil J. Ashweek, Collin Regan
  • Patent number: 7816406
    Abstract: The present invention provides quinolone analogs which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing quinolone analogs, and methods of using the same.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: October 19, 2010
    Assignee: Cylene Pharmaceuticals, Inc.
    Inventors: Jeffrey P. Whitten, Fabrice Pierre, Collin Regan, Michael Schwaebe, Johnny Y. Nagasawa, Peter Chua
  • Patent number: 7652134
    Abstract: The present invention relates to methods of preparing compounds having formula (1), (2), (5), and ((6A)-(6D)) comprising contacting the corresponding ester, an amine with formula NHR1R2, and a Lewis acid having formula MLn, wherein L is a halogen atom or an organic radical, n is 3-5, and M is a group III elemental atom, a group IV elemental atom, As, Sb, V or Fe, wherein A, B, V, X, Z, W, R1, R2, R5, Z1, Z2, Z3, Z4, Z5, Z6, Z7, and Z8 are substituents. Z4, Z5, Z6, Z7, and Z8 are substituents.
    Type: Grant
    Filed: June 9, 2005
    Date of Patent: January 26, 2010
    Assignee: Cylene Pharmaceuticals, Inc.
    Inventors: Jeffrey P. Whitten, Fabrice Pierre, Collin Regan, Michael Schwaebe, George Petros Yiannikouros, Michael Jung
  • Patent number: 7329669
    Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: February 12, 2008
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Yun-Fei Zhu, Collin Regan, Jaimie K Rueter, Zhiqiang Guo, Yongsheng Chen, Charles Q Huang
  • Publication number: 20070015778
    Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
    Type: Application
    Filed: June 2, 2006
    Publication date: January 18, 2007
    Applicant: Neurocrine Biosciences, Inc.
    Inventors: Yun-Fei Zhu, Collin Regan, Jaimie Rueter, Zhiqiang Guo, Yongsheng Chen, Charles Huang
  • Patent number: 7071200
    Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
    Type: Grant
    Filed: July 6, 2004
    Date of Patent: July 4, 2006
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Yun-Fei Zhu, Collin Regan, Jaimie K. Rueter, Zhiqiang Guo, Yongsheng Chen, Charles Q. Huang
  • Publication number: 20060074089
    Abstract: The present invention provides quinolone analogs which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing quinolone analogs, and methods of using the same.
    Type: Application
    Filed: September 16, 2005
    Publication date: April 6, 2006
    Inventors: Jeffrey Whitten, Fabrice Pierre, Collin Regan, Michael Schwaebe, George Yiannikouros, Michael Jung
  • Publication number: 20060063761
    Abstract: The present invention relates to methods of preparing compounds having formula (1), (2), (5), and ((6A)-(6D)) comprising contacting the corresponding ester, an amine with formula NHR1R2, and a Lewis acid having formula MLn, wherein L is a halogen atom or an organic radical, n is 3-5, and M is a group III elemental atom, a group IV elemental atom, As, Sb, V or Fe, wherein A, B, V, X, Z, W, R1, R2, R5, Z1, Z2, Z3, Z4, Z5, Z6, Z7, and Z8 are substituents. Z4, Z5, Z6, Z7, and Z8 are substituents.
    Type: Application
    Filed: June 9, 2005
    Publication date: March 23, 2006
    Inventors: Jeffrey Whitten, Fabrice Pierre, Collin Regan, Michael Schwaebe, George Yiannikouros, Michael Jung
  • Publication number: 20060025468
    Abstract: The present invention relates to chiral pyrrolidine derivatives; and methods for preparing compounds thereof. The chiral pyrrolidine derivatives of the present invention may be used as intermediates for pharmaceutical and agricultural chemicals.
    Type: Application
    Filed: July 29, 2004
    Publication date: February 2, 2006
    Inventors: Jeffrey Whitten, Michael Schwaebe, Collin Regan
  • Publication number: 20050043338
    Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
    Type: Application
    Filed: July 6, 2004
    Publication date: February 24, 2005
    Applicant: Neurocrine Biosciences, Inc.
    Inventors: Yun-Fei Zhu, Collin Regan, Jaimie Rueter, Zhiqiang Guo, Yongsheng Chen, Charles Huang
  • Publication number: 20040162290
    Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women.
    Type: Application
    Filed: November 10, 2003
    Publication date: August 19, 2004
    Applicant: Neurocrine Biosciences, Inc.
    Inventors: Zhiqiang Guo, Dongpei Wu, Chen Chen, Fabio Tucci, Collin Regan
  • Patent number: 6677340
    Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1, R2, R3a, R3b, R4, R5, and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: January 13, 2004
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Zhiqiang Guo, Dongpei Wu, Chen Chen, Fabio Tucci, Collin Regan
  • Publication number: 20030130282
    Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women.
    Type: Application
    Filed: August 2, 2002
    Publication date: July 10, 2003
    Applicant: Neurocrine Biosciences, Inc.
    Inventors: Zhiqiang Guo, Dongpei Wu, Chen Chen, Fabio Tucci, Collin Regan